A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. (April 2022)

• Record Type: Journal Article
• Authors: Tagliamento, Marco; Bironzo, Paolo; Curcio, Hubert; De Luca, Emmanuele; Pignataro, Daniele; Rapetti, Simonetta G.; Audisio, Marco; Bertaglia, Valentina; Paratore, Chiara; Bungaro, Maristella; Olmetto, Emanuela; Artusio, Elisa; Reale, Maria Lucia; Zichi, Clizia; Capelletto, Enrica; Carnio, Simona; Buffoni, Lucio; Passiglia, Francesco; Novello, Silvia; Scagliotti, Giorgio Vittorio; Di Maio, Massimo
• Is Part Of: Critical reviews in oncology/hematology. Volume 172(2022)
• Publication Date: 2022-04
• Subjects: MM malignant mesothelioma -- OS overall survival -- PFS progression-free survival -- ICIs immune checkpoint inhibitors -- CTLA-4 cytotoxic T-lymphocyte antigen-4 -- PD-1 programmed cell death protein-1 -- PD-L1 programmed death-ligand 1 -- asMM advanced stage malignant mesothelioma -- mAbs monoclonal antibodies -- ASCO American Society of Clinical Oncology -- ESMO European Society of Medical Oncology -- IASLC International Association for the Study of Lung Cancer -- ELCC European Lung Cancer Congress -- HR hazard ratio -- CI confidence interval -- ORR objective response rare -- FDA Food and Drug Administration -- EMA European Medicines Agency -- q2w every two weeks -- q3w every three weeks -- ECOG Eastern Cooperative Oncology Group -- PS performance status -- IHC immunohistochemistry -- DoT duration of treatment -- RECIST Response Evaluation Criteria in Solid Tumors -- PD-L1+ PD-L1 positive -- PD-L1- PD-L1 negative -- MPM malignant pleural mesothelioma -- mRECIST modified RECIST -- iRECIST immune RECIST -- DoR duration of response -- RR response rate -- PR partial response -- SD stable disease -- BAP1 BRCA1 associated protein 1 -- CAR-T chimeric antigen receptor T-cell; Mesothelioma -- Immune checkpoint inhibitors -- Nivolumab -- Pembrolizumab -- Avelumab; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2022.103639
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Introduction: Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM. Methods: A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed. Results: We selected 13 studies including 888 patients. ORR and DCR were 18.1% (95% confidence interval [CI] 13.9–22.8%) and 55.4% (95% CI: 48.1–62.5%), respectively. Median PFS and OS ranged from 2.1 to 5.9 and from 6.7 to 20.9 months, respectively. ORR according to PD-L1 was 27.0% (95% CI: 18.7–36.2%). Conclusions: Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking. Graphical Abstract: ga1 Highlights: First systematic review on anti-PD-1/PD-L1 agents in pre-treated advanced mesothelioma. Anti PD-1/PD-L1 agents could lead to 18.1% response rate and 55.4% disease-control rate . This result compares favorably with historical data with single-agent chemotherapy. Predictive factors of ICIs efficacy are still lacking.